UnitedHealth Group (UNH)

Don't let the bad news scare you away from these high-yield dividend payers.

The Pennant Group’s second quarter was marked by strong revenue growth and a positive market response, reflecting management’s focus on operational execution and strategic expansion. CEO Brent Guerisoli credited performance to the company’s emphasis on leadership development, clinical quality, and margin improvement across its service lines. The quarter also benefited from Pennant’s ability to integrate new acquisitions and drive organic growth, especially within its home health and hospice operations. Management highlighted the resilience of its operating model despite challenges in reimbursement and regulatory pressures, with President John Gochnour noting, “Our excellent clinical and cultural performance continues to translate to record financial results.”

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 9.3%. This drop is a stark contrast from the S&P 500’s 5.4% gain.

Health insurance company UnitedHealth (NYSE:UNH) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 12.9% year on year to $111.6 billion. On the other hand, the company’s full-year revenue guidance of $446.8 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $4.08 per share was 8.3% below analysts’ consensus estimates.

UnitedHealth’s second quarter results drew a negative market reaction, as management pointed to higher-than-expected medical costs and operational missteps as central causes. CEO Stephen Hensley described the period as “challenging,” highlighting misjudged pricing assumptions in Medicare Advantage and commercial businesses, as well as a need for fundamental reorientation in some segments. Management acknowledged that rising service intensity, increased provider billing practices, and delayed operational responses contributed to margin pressures. Hensley emphasized, “We’ve made pricing and operational mistakes … they are getting the needed attention.”

A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.

July CPI showed airline fares up 4% and gasoline down 1.9%, sparking a major airline stock rally as carriers enjoy better margins.

Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic growth. At the heart of these concerns are the tariff policies enacted by former President Donald Trump, which many experts fear could simultaneously drive

UnitedHealth will sell 164 healthcare facilities in a DOJ settlement over its Amedisys deal while missing Q2 earnings and reaffirming 2025 guidance.

Senior living provider The Pennant Group (NASDAQ:PNTG) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 30.1% year on year to $219.5 million. The company’s full-year revenue guidance of $870.2 million at the midpoint came in 2.1% above analysts’ estimates. Its GAAP profit of $0.20 per share was 17.9% below analysts’ consensus estimates.

They all offer great value right now.

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.1% in the morning session after the company reported better-than-expected second-quarter 2025 financial results, beating revenue and earnings forecasts. The genomics company announced revenue of $39.77 million, a 10.4% increase year-over-year, which surpassed analysts' expectations by 7.6%. Its non-GAAP loss of $0.13 per share was also 21.5% narrower than anticipated. This performance was supported by a significant improvement in profitability, with the company's operating margin reaching negative 113%, a substantial improvement from negative 488% in the same quarter last year. The results suggest growing adoption of the company’s sequencing platforms, such as the Revio and Onso systems, which are used by researchers to analyze genomes with high accuracy.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.5% in the morning session after the company reported strong second-quarter results that surpassed Wall Street's expectations for both revenue and profitability. The company announced revenue of $172.9 million, a 12.9% increase from the prior year and a significant 24% above analyst estimates. Profitability was a major bright spot, with GAAP earnings per share of $0.28, crushing the consensus forecast of a $0.37 loss per share. This impressive performance overshadowed a slightly cautious outlook for the upcoming third quarter, where the company's revenue guidance of $142 million came in just below analyst projections. Investors focused on the strong current performance, seeing the substantial earnings beat as a positive sign for the company's operational efficiency and market position.

Shares of medical device company ICU Medical (NASDAQ:ICUI) fell 10.5% in the morning session after the company reported second-quarter results where a significant earnings beat was overshadowed by a year-over-year revenue decline and concerning cash flow performance. The medical device company reported a GAAP profit of $1.43 per share, significantly reversing a loss from the prior year and handily beating analyst expectations. However, investors appeared to focus on the 8% year-over-year decline in revenue, which landed at $548.9 million, even though it slightly surpassed analyst forecasts. Furthermore, the company's free cash flow was a negative $8.49 million, a stark reversal from a positive $62.67 million in the same period last year, indicating pressure on its cash generation. Despite the company also issuing full-year profit guidance that was well ahead of Wall Street estimates, the revenue dip and negative cash flow seemingly weighed more heavily on investor sentiment.

UnitedHealth will divest 164 healthcare locations and Amedisys will pay a $1.1 million penalty under a DOJ settlement resolving antitrust concerns over a $3.3 billion deal.

UnitedHealth is implementing artificial intelligence to improve efficiency.

Recent economic data from the United States has presented a nuanced picture of the nation's labor market, with a slight uptick in unemployment benefit applications alongside a significantly lower-than-expected nonfarm jobs report. While the increase in jobless claims remains within its recent range and is not immediately indicative of a

The United States economy is currently grappling with a complex and often contradictory narrative, marked by recent weak payrolls data, a discernible slowdown in the labor market, and persistent inflationary pressures. This confluence of factors is sending ripples through the stock market, prompting increased volatility and a significant re-evaluation of

Market volatility could increase in the months ahead, but these stocks should hold up well.

UnitedHealth Group has been hit with a series of bad news lately.

Shares of medical device company Artivion (NYSE:AORT) jumped 3% in the morning session after investment firm Stifel raised its price target on the stock to $36 from $30, while maintaining a Buy rating. The adjustment followed Stifel's conversations with six physicians who utilized Artivion's aortic arch dissection repair stent (AMDS) after its FDA approval. The doctors reportedly offered positive commentary about the device, noting it simplified a complex procedure and enhanced results over existing treatments. This feedback reinforced Stifel's optimistic view on the technology's launch and its potential within what the firm estimated was a $150 million US market.

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 4.4% in the afternoon session after the company reported mixed second-quarter financial results, where a massive net loss overshadowed a revenue beat and raised guidance. The contract research organization posted revenues of $710.3 million, which exceeded analysts' expectations. However, investors focused on a staggering GAAP net loss of $374.9 million for the quarter. This loss resulted primarily from a non-cash goodwill impairment charge of $309.1 million. A goodwill impairment is an accounting adjustment made when the value of a company's assets declined. Fortrea attributed this charge to its own falling share price and market-driven interest rate increases. Further concerns arose from a weak book-to-bill ratio of 0.79x, which indicated the company secured less new business than it billed during the period.

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its full-year outlook. The medical device maker reported second-quarter earnings per share of $0.60 on revenue of $64.2 million, which beat Wall Street's expectations. The company's sales jumped 15% from the previous year, pushed by higher prices and a 7% increase in the number of products sold. Strong international sales for its Artegraft product also contributed to the growth. Looking ahead, LeMaitre lifted its full-year 2025 revenue forecast to $251 million and increased its earnings guidance, signaling management's confidence in continued strong performance.